Home › NDC Lookup › Ingredients › Anhydrous Citric Acid, Dextrose Monohydr... › 23731-6051-03
Anticoagulant Citrate Dextrose A Anhydrous Citric Acid, Dextrose Monohydrate, and Trisodium Citrate Dihydrate .245 g/10mL; .073 g/10mL; .22 g/10mL Solution, 30 mL — NDC 23731-6051-03 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

Anticoagulant Citrate Dextrose A Anhydrous Citric Acid, Dextrose Monohydrate, and Trisodium Citrate Dihydrate .245 g/10mL; .073 g/10mL; .22 g/10mL Solution, 30 mL — NDC 23731-6051-3 (Billing 23731-6051-03)

by Citra Labs LLC · 30 mL in 1 VIAL, SINGLE-USE

This is a package of 30 mL of Anticoagulant Citrate Dextrose A Anhydrous Citric Acid, Dextrose Monohydrate, and Trisodium Citrate Dihydrate .245 g/10mL; .073 g/10mL; .22 g/10mL Solution from Citra Labs LLC, marketed since Aug 2003 and currently FDA-listed.

NDC 23731-6051-03
🏷️ FDA NDC (as labeled) 23731-6051-3 billing pads the package segment with a zero
This package
Contains30 mL Pack sizes3 compare ↓
Product page 23731-6051-01 Also comes in: 10 vials 23731-6051-1 25 vials 23731-6051-2
Rx only Brand On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 8, 2026 · this listing last changed Oct 8, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 23731-6051-3 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
23731 labeler · 6051 product · 3 package
Package marketed since
Aug 26, 2003
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Billing quantity
30 mL per package
Barcode (UPC-A, from the NDC)
3 2373160513 0
FDA record last changed
Oct 8, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 23731-6051-3
Product NDC 23731-6051
11-digit billing NDC 23731605103
NCPDP billing unit ML — per mL (volume)
UNII LX22YL083G, XF417D3PSL, B22547B95K
Application # BN020037
SPL Set ID 5bcd261e-ebba-4ecb-af22-e5aaeb04499b
Established class (EPC) Calculi Dissolution Agent; Anti-coagulant
Mechanism of action Acidifying Activity; Calcium Chelating Activity
Physiologic effect Decreased Coagulation Factor Activity
DEA schedule Non-controlled
Marketing category NDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2003-08-26
Route EXTRACORPOREAL
Dosage form SOLUTION
Substance DEXTROSE MONOHYDRATE; ANHYDROUS CITRIC ACID; TRISODIUM CITRATE DIHYDRATE

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GCN Seq No 062433
GCN 98209
HICL code 015151
Ingredient (HICL) Dextrose/Sod Citrate/Citric Ac
HIC1 code M
Therapeutic class — broad (HIC1) Blood
HIC2 code M9
Therapeutic class — intermediate (HIC2) Drugs Given To Alter Blood Coagulation
HIC3 code M9J
Therapeutic class — specific (HIC3) Citrates As Anticoagulants
AHFS code 20:12.04.92
AHFS class Anticoagulants, Miscellaneous
FDB label name ACD-A 30 ML VIAL
FDB brand name Acd-A
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 062433
  • GCN: 98209
  • HICL (First Databank): 015151
  • AHFS class code: 20:12.04.92
Why two NDCs? The FDA registers this code as 23731-6051-3 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 23731-6051-03. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Label name ACD-A 30 ML VIAL Ingredient Dextrose/Sod Citrate/Citric Ac

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
ℹ️
No price is published for this exact package yet. CMS surveys NADAC per package size, so a different pack of the same drug often has one.
Try another pack size: 10 vials 25 vials
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
23731-6051-01 23731-6051-1 Main listing 10 VIAL, SINGLE-USE in 1 CASE / 30 mL in 1 VIAL, SINGLE-USE 2003-08-26 — Active
23731-6051-02 23731-6051-2 25 VIAL, SINGLE-USE in 1 CASE / 30 mL in 1 VIAL, SINGLE-USE 2003-08-26 — Active
23731-6051-03 You're viewing this 30 mL in 1 VIAL, SINGLE-USE 2003-08-26 — Active

Pack size FAQ

What quantity is in this package?
This package contains 30 mL — 30 ml in 1 vial, single-use.
What NDC number is used to bill for this package of Anticoagulant Citrate Dextrose A Anhydrous Citric Acid, Dextrose Monohydrate, and Trisodium Citrate Dihydrate .245 g/10mL; .073 g/10mL; .22 g/10mL Solution?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Anticoagulant Citrate Dextrose A .245 g/10mL; .073 g/10mL; .22 g/10mLthis 23731-6051-03 Citra 30 ml — — FDA listed —
About this product: this is the brand-name version. We did not find an FDA-approved generic match for this exact strength, form and route.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2003
On the market since
Aug 2003
📍
2026
Currently FDA-listed
23 years listed
🔒
·
No generic listed yet
brand only
ℹ️No FDA-approved generic found

We did not find an FDA-approved generic match for this exact strength, form and route.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

A current SPL was checked, but it does not contain a structured or narrative inactive-ingredient list for this product. This does not mean the product has no inactive ingredients.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerCitra Labs LLC
FDA applicationBN020037 (NDA)
Labeler code23731
First marketedAug 2003
Product typeHuman Prescription Drug
Portfolio2 products on file

More NDCs from Citra Labs LLC labeler code 23731

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications ⚠️ Warnings 🤒 Adverse Reactions 🤰 Pregnancy 🧒 Pediatric Use 🆘 Overdosage 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📦 Storage and Handling 📋 Description 💬 Information for Patients ⚠️ Precautions 📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 50 words ▾

Indications and Usage Anticoagulant Citrate Dextrose Solution, Solution A, U.S.P. (ACD-A), is intended for use as an anticoagulant in the extracorporeal blood processing with Autologous PRP Systems in production of platelet rich plasma (PRP). Refer to the manufacturer's Operator's Manual of the Autologous PRP System for the Directions for Use.

⏱️ Dosage and Administration 19 words ▾

Dosage and Administration Refer to the manufacturer's Operator's Manual of the Autologous PRP System for the Directions for Use.

⛔ Contraindications 6 words ▾

Contraindications NOT FOR DIRECT INTRAVENOUS INFUSION

⚠️ Warnings 6 words ▾

Warnings NOT FOR DIRECT INTRAVENOUS INFUSION

🤒 Adverse Reactions 27 words ▾

Adverse Reactions Not applicable. This product is used as an anticoagulant in the extracorporeal blood processing with Autologous PRP Systems in production of platelet rich plasma (PRP).

🤰 Pregnancy 19 words ▾

Pregnancy Long-term studies in animals have not been performed to evaluate the effects of ACD- A on pregnant women.

🧒 Pediatric Use 14 words ▾

Pediatric Use The safety and effectiveness of ACD-A in children have not been established.

🆘 Overdosage 26 words ▾

Overdosage Not applicable. This product is used as an anticoagulant in the extracorporeal blood processing with Autologous PRP systems in production of platelet rich plasma (PRP).

🧬 Clinical Pharmacology 26 words ▾

Clinical Pharmacology ACD-A acts as an anticoagulant by the action of the citrate ion chelating free ionized calcium, thus making calcium unavailable to the coagulation system.

📦 How Supplied / Storage and Handling 68 words ▾

How Supplied Anticoagulant Citrate Dextrose Solution, Solution A, U.S.P., (ACD-A) REF SIZE CASE PN 9350-10 30 mL 10 Vials/Case PN 9350-25 30 mL 25 Vials/Case It is recommended that the product be stored at ambient room temperature, 24 °C (75 °F); however, the product can be stored between 15 °C (59 °F) and 30 °C (86 °F). Protect from freezing and exposure to excessive heat should be minimized.

📦 Storage and Handling 43 words ▾

It is recommended that the product be stored at ambient room temperature, 24 °C (75 °F); however, the product can be stored between 15 °C (59 °F) and 30 °C (86 °F). Protect from freezing and exposure to excessive heat should be minimized.

📋 Description 67 words ▾

Description Anticoagulant Citrate Dextrose Solution, Solution A, U.S.P., (ACD-A), is a sterile, non-pyrogenic solution of citric acid, sodium citrate, and dextrose, in water for injection. Each 10 mL of solution contains: Citric Acid, anhydrous, USP 0.073 g Sodium Citrate, dihydrate, USP 0.220 g Dextrose, monohydrate, USP 0.245 g Water for Injection, USP q.s. pH: 4.5 –

5.5Single patient use only, on a single occasion. single use

💬 Information for Patients 4 words ▾

Information for Patients None.

⚠️ Precautions 106 words ▾

Precautions General Aseptic technique must be maintained at all times. ACD-A solution is a clear and colorless solution. If the product shows any cloudiness or turbidity, the product should be discarded.

The closure system provides a biological barrier and should be intact – discard product if system is compromised. Information for Patients None. Carcinogenesis, mutagenesis, impairment of fertility Long-term studies in animals have not been performed to evaluate the carcinogenic potential of ACD-A.

Pregnancy Long-term studies in animals have not been performed to evaluate the effects of ACD- A on pregnant women. Pediatric Use The safety and effectiveness of ACD-A in children have not been established.

📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 20 words ▾

Carcinogenesis, mutagenesis, impairment of fertility Long-term studies in animals have not been performed to evaluate the carcinogenic potential of ACD-A.

📄 Package Label / Principal Display Panel ~1 min read ▾

PRINCIPAL DISPLAY PANEL - 10 Vial Case Label C E 0044 ACD-A Anticoagulant Citrate Dextrose Solution, 10 Vials / Case Solution A, U.S.P., ACD-A, 30 mL REF PN 9350-10 WARNING: NOT FOR DIRECT INTRAVENOUS INFUSION Used as an anticoagulant in the extracorporeal blood processing with Autologous PRP Systems in production of platelet rich plasma (PRP). Refer to PRP Systems manufacturer's Directions for Use. Manufactured & Distributed by: Citra Labs A Biomet Inc.

Company. Citra Labs, LLC. 55 Messina Drive, Braintree, MA 02184 1-800-299-3411 EC REP Authorized Representative: Biomet Global Supply Chain Center B.V.

Hazeldonk 6530 4836 LD Breda The Netherlands STERILE • NON-PYROGENIC Composition per 10 mL of Solution: Citric Acid, (Anhydrous), U.S.P. 0.073 g. Sodium Citrate, (Dihydrate), U.S.P.

0.220 g. Dextrose, (Monohydrate), U.S.P. 0.245 g.

CAUTION: Single Procedure Use-Discard Unused Portion Do Not Use Unless Solution is Clear and Seal is Intact. Store Between 15 °C - 30 °C (59 °F - 86 °F). RX Only: EXP DATE LOT LA9350-10B 01/20 symbols label

PRINCIPAL DISPLAY PANEL - 25 Vial Case Label C E 0044 ACD-A Anticoagulant Citrate Dextrose Solution, 25 Vials / Case Solution A, U.S.P., ACD-A, 30 mL REF PN 9350-25 WARNING: NOT FOR DIRECT INTRAVENOUS INFUSION Used as an anticoagulant in the extracorporeal blood processing with Autologous PRP Systems in production of platelet rich plasma (PRP). Refer to PRP Systems manufacturer's Directions for Use. Manufactured & Distributed by: Citra Labs A Biomet Inc.

Company. Citra Labs, LLC. 55 Messina Drive, Braintree, MA 02184 1-800-299-3411 EC REP Authorized Representative: Biomet Global Supply Chain Center B.V.

Hazeldonk 6530 4836 LD Breda The Netherlands STERILE • NON-PYROGENIC Composition per 10 mL of Solution: Citric Acid, (Anhydrous), U.S.P. 0.073 g. Sodium Citrate, (Dihydrate), U.S.P.

0.220 g. Dextrose, (Monohydrate), U.S.P. 0.245 g.

CAUTION: Single Procedure Use-Discard Unused Portion Do Not Use Unless Solution is Clear and Seal is Intact. Store Between 15 °C - 30 °C (59 °F - 86 °F). RX Only: EXP DATE LOT LA9350-25 01/20 label

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Anhydrous Citric Acid, Dextrose Monohydrate, and Trisodium Citrate Dihydrate — the ingredient across all brands.

Top reported reactions

Product Packaging Confusion2
Intercepted Product Selection Error1
Product Barcode Issue1
Product Name Confusion1

Reporter sex

3 reports
Reports over time (by year) — tap or hover for the count & year
2022 2023 2024 2026 2 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

About this NDC listing & data coverage

Finished prescription product
What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos ✓ Available
Inactive ingredients (structured) — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available.
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Citra Labs LLC. Listing status can change — the directory data on this page refreshes weekly.
Does this product come in other package sizes?
Yes — the FDA directory lists 2 other package presentations of this same product, including 10 vials (23731-6051-01), 25 vials (23731-6051-02). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
Citra Labs LLC is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 23731-6030-01 · Citra 23731-7000-05 · Citra →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.